| Bioactivity | PVP-037.2 is a TLR7/8 agonist. PVP-037.2 can serve as an adjuvant to enhance vaccine-induced TH1 type immune responses, increasing the production of antigen-specific antibodies IgG1 and IgG2c[1]. |
| Invitro | PVP-037.2 (0.1-100 μM，24 小时) 以浓度依赖的方式诱导了人类老年外周血单核细胞 (PBMCs) 中的 TNF 和 IL-1β 的产生[1]。PVP-037.2 (100 μM，20-24 小时) 具有依赖于 TLR7/8 的免疫调节特性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> PVP-037.2 相关抗体: |
| In Vivo | PVP-037.2 (3 mg/kg，静脉注射，给药后 0-8 小时测定) 在 C57BL/6J 成年小鼠 (体重为 20 至 30 g) 中具有高血浆清除率且几乎无溶血活性[1]。PVP-037.2 (每只小鼠 100 nmol，静脉注射，单次免疫接种) 在接种三价重组 rHA 流感疫苗 Flublok及 SARS-CoV-2 刺突蛋白的 C57BL/6J 小鼠中具有强大的佐剂作用[1]。与单独使用 PVP-037.2 相比，PVP-037.2 O/W 乳液制剂 (每只小鼠 10 nmol，静脉注射，第 42 天测定 IgG 滴度) 可使野生型 C57BL/6J 小鼠的先天免疫激活能力增强[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| Formula | C23H20F3N5O |
| Molar Mass | 439.43 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Soni D, et al. From hit to vial: Precision discovery and development of an imidazopyrimidine TLR7/8 agonist adjuvant formulation[J]. Science Advances, 2024, 10(27): eadg3747. |